Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Blocking Galactin-3 Binding Prevents Metastasis in Various Cancers

By BiotechDaily International staff writers
Posted on 03 Apr 2013
A small molecule derived from a glycoprotein that protects cod from freezing binds and inhibits galectin-3 and prevents metastasis in various cancers, including prostate adenocarcinoma.

Galectin-3 (gal3) is one of the 14 recognized mammalian lectins. This protein weighs approximately 30 kDa and, like all galectins, contains a carbohydrate-recognition-binding domain of about 130 amino acids that enables the specific binding of beta-galactosides. Gal3 is expressed in cells in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. This protein has been shown to be involved in cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis. Gal3 recognizes the Thomsen-Friedenreich disaccharide (TFD, galactose-N-acetylgalactosamine) that is present on the surface of most cancer cells and is involved in promoting angiogenesis, tumor-endothelial cell adhesion, and metastasis of prostate cancer cells, as well as evading immune surveillance through killing of activated T-cells.

Investigators at the University of Maryland School of Medicine (Baltimore, USA) isolated a glycopeptide (TDF100) from cod that presents the disaccharide (galactose-N-acetylgalactosamine) recognized by gal3.

They reported in the March 11, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that TFD100 blocked gal3-mediated angiogenesis, tumor-endothelial cell interactions, and metastasis of prostate cancer cells in mice at nanomolar levels. Apoptosis of activated T-cells—induced by either recombinant gal3 or prostate cancer patient serum-associated gal3—was inhibited by nanomolar concentrations of TFD100.

“This study is among the first to explore the therapeutic utility of a bioactive cod TFD-containing glycopeptide to inhibit prostate cancer from progressing,” said senior author Dr. Hafiz Ahmed, assistant professor of biochemistry and molecular biology at the University of Maryland School of Medicine. “The TFD (Thomsen-Friedenreich disaccharide) antigen in the fish protein is hidden in normal human cells but is exposed on the surface of cancer cells and is believed to play a key role in how cancer spreads.”

“The use of natural dietary products with antitumor activity is an important and emerging field of research,” said Dr. Ahmed. “Understanding how these products work could allow us to develop foods that also act as cancer therapeutics and agents for immunotherapy.”

Related Links:
University of Maryland School of Medicine




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.